Sierra’s not-so-nimble Jak scores at last
Momelotinib, a Jak inhibitor that has been through four companies, yields a positive result in its pivotal Momentum trial.
Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
JP Morgan 2022 – Abbvie looks to crack the cystic fibrosis code
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
JP Morgan 2022 – Sarepta gets another bite at the gene therapy cherry
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
JP Morgan 2022 – Beam and Mammoth hook big pharma partners
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Huntington’s hurt continues
Annexon becomes the latest group to provide a confusing update in the disease.
